The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) on behalf of investors concerning the Company’s possible violations of federal securities laws.

On July 30, 2026, the Company reported second quarter earnings, including revenue of $90.2 million, reflecting a 3.2% year over year decline. Further, the Company reported a 10% revenue decline for RUCONEST. The Company stated, among other things, that “the year-over-year decline reflected… temporary inventory normalization.” The Company also cut its full year revenue guidance approximately $30 million at the midpoint to $375 to $395 million and stated “[a]t the midpoint of our guidance range, RUCONEST U.S. revenue is expected to decline approximately 3% for the full year.”

On this news, Pharming Group shares fell $1.26 or 10.5% per share to close at $10.75, on July 30, 2026, thereby injuring investors.